-
A global phase 3 study of serplulimab plus chemotherapy as first-line treatment for advanced squamous non-small-cell lung cancer (ASTRUM-004)
A recent study shows that First-line serplulimab plus chemotherapy improves PFS and OS and promises…
A recent study shows that First-line serplulimab plus chemotherapy improves PFS and OS and promises…